| Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFβ, in advanced solid tumors J Strauss, CR Heery, J Schlom, RA Madan, L Cao, Z Kang, E Lamping, ... Clinical Cancer Research 24 (6), 1287-1295, 2018 | 369 | 2018 |
| Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial RA Madan, M Mohebtash, PM Arlen, M Vergati, M Rauckhorst, ... The lancet oncology 13 (5), 501-508, 2012 | 363 | 2012 |
| Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer JL Gulley, PM Arlen, RA Madan, KY Tsang, MP Pazdur, L Skarupa, ... Cancer Immunology, Immunotherapy 59, 663-674, 2010 | 354 | 2010 |
| Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial CR Heery, G O'Sullivan-Coyne, RA Madan, L Cordes, A Rajan, ... The Lancet Oncology 18 (5), 587-598, 2017 | 310 | 2017 |
| Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy WD Stein, JL Gulley, J Schlom, RA Madan, W Dahut, WD Figg, Y Ning, ... Clinical Cancer Research 17 (4), 907-917, 2011 | 272 | 2011 |
| Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer RA Madan, PM Arlen, M Mohebtash, JW Hodge, JL Gulley Expert opinion on investigational drugs 18 (7), 1001-1011, 2009 | 258 | 2009 |
| Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations F Karzai, D VanderWeele, RA Madan, H Owens, LM Cordes, A Hankin, ... Journal for immunotherapy of cancer 6, 1-12, 2018 | 257 | 2018 |
| Immunotherapy of prostate cancer: facts and hopes M Bilusic, RA Madan, JL Gulley Clinical Cancer Research 23 (22), 6764-6770, 2017 | 253 | 2017 |
| Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors M Bilusic, CR Heery, JM Collins, RN Donahue, C Palena, RA Madan, ... Journal for immunotherapy of cancer 7, 1-8, 2019 | 216 | 2019 |
| Role of antigen spread and distinctive characteristics of immunotherapy in cancer treatment JL Gulley, RA Madan, R Pachynski, P Mulders, NA Sheikh, J Trager, ... JNCI: Journal of the National Cancer Institute 109 (4), djw261, 2017 | 205 | 2017 |
| Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer YM Ning, JL Gulley, PM Arlen, S Woo, SM Steinberg, JJ Wright, ... Journal of clinical oncology 28 (12), 2070-2076, 2010 | 179 | 2010 |
| Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy RA Madan, JL Gulley, J Schlom, SM Steinberg, DJ Liewehr, WL Dahut, ... Clinical Cancer Research 14 (14), 4526-4531, 2008 | 167 | 2008 |
| Sicca syndrome associated with immune checkpoint inhibitor therapy BM Warner, AN Baer, EJ Lipson, C Allen, C Hinrichs, A Rajan, E Pelayo, ... The oncologist 24 (9), 1259-1269, 2019 | 159 | 2019 |
| Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression RA Madan, JL Gulley, T Fojo, WL Dahut The oncologist 15 (9), 969-975, 2010 | 159 | 2010 |
| A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer M Mohebtash, KY Tsang, RA Madan, NY Huen, DJ Poole, C Jochems, ... Clinical Cancer Research 17 (22), 7164-7173, 2011 | 156 | 2011 |
| Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer JL Gulley, RA Madan, KY Tsang, C Jochems, JL Marté, B Farsaci, ... Cancer immunology research 2 (2), 133-141, 2014 | 148 | 2014 |
| First-in-human phase I trial of a tumor-targeted cytokine (NHS-IL12) in subjects with metastatic solid tumors J Strauss, CR Heery, JW Kim, C Jochems, RN Donahue, AS Montgomery, ... Clinical Cancer Research 25 (1), 99-109, 2019 | 147 | 2019 |
| Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role J Huang, C Jochems, T Talaie, A Anderson, A Jales, KY Tsang, ... Blood, The Journal of the American Society of Hematology 120 (15), 3030-3038, 2012 | 138 | 2012 |
| Phase I trial of a yeast-based therapeutic cancer vaccine (GI-6301) targeting the transcription factor brachyury CR Heery, BH Singh, M Rauckhorst, JL Marté, RN Donahue, I Grenga, ... Cancer immunology research 3 (11), 1248-1256, 2015 | 134 | 2015 |
| Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma A Rajan, CR Heery, A Thomas, AL Mammen, S Perry, G O’Sullivan Coyne, ... Journal for immunotherapy of cancer 7, 1-12, 2019 | 126 | 2019 |
James L. GulleyNational Cancer InstituteEmail verificata su mail.nih.gov